Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9316969rdf:typepubmed:Citationlld:pubmed
pubmed-article:9316969lifeskim:mentionsumls-concept:C2709248lld:lifeskim
pubmed-article:9316969lifeskim:mentionsumls-concept:C0243192lld:lifeskim
pubmed-article:9316969lifeskim:mentionsumls-concept:C0001480lld:lifeskim
pubmed-article:9316969lifeskim:mentionsumls-concept:C0018549lld:lifeskim
pubmed-article:9316969lifeskim:mentionsumls-concept:C0032824lld:lifeskim
pubmed-article:9316969lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:9316969lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:9316969lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:9316969lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:9316969lifeskim:mentionsumls-concept:C0599946lld:lifeskim
pubmed-article:9316969lifeskim:mentionsumls-concept:C0917866lld:lifeskim
pubmed-article:9316969lifeskim:mentionsumls-concept:C0332324lld:lifeskim
pubmed-article:9316969pubmed:issue3lld:pubmed
pubmed-article:9316969pubmed:dateCreated1997-10-16lld:pubmed
pubmed-article:9316969pubmed:abstractTextLemakalim, an adenosine triphosphate (ATP)-sensitive potassium (K+(ATP)) channel agonist, causes profound pulmonary vasodilation in conscious dogs, which is attenuated during halothane anesthesia. The goal of the present study was to investigate the mechanism responsible for this attenuating effect of halothane.lld:pubmed
pubmed-article:9316969pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9316969pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9316969pubmed:languageenglld:pubmed
pubmed-article:9316969pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9316969pubmed:citationSubsetAIMlld:pubmed
pubmed-article:9316969pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9316969pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9316969pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9316969pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9316969pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9316969pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9316969pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9316969pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9316969pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9316969pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9316969pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9316969pubmed:statusMEDLINElld:pubmed
pubmed-article:9316969pubmed:monthSeplld:pubmed
pubmed-article:9316969pubmed:issn0003-3022lld:pubmed
pubmed-article:9316969pubmed:authorpubmed-author:MurrayP APAlld:pubmed
pubmed-article:9316969pubmed:authorpubmed-author:SekiSSlld:pubmed
pubmed-article:9316969pubmed:authorpubmed-author:HoribeMMlld:pubmed
pubmed-article:9316969pubmed:issnTypePrintlld:pubmed
pubmed-article:9316969pubmed:volume87lld:pubmed
pubmed-article:9316969pubmed:ownerNLMlld:pubmed
pubmed-article:9316969pubmed:authorsCompleteYlld:pubmed
pubmed-article:9316969pubmed:pagination625-34lld:pubmed
pubmed-article:9316969pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:9316969pubmed:meshHeadingpubmed-meshheading:9316969-...lld:pubmed
pubmed-article:9316969pubmed:meshHeadingpubmed-meshheading:9316969-...lld:pubmed
pubmed-article:9316969pubmed:meshHeadingpubmed-meshheading:9316969-...lld:pubmed
pubmed-article:9316969pubmed:meshHeadingpubmed-meshheading:9316969-...lld:pubmed
pubmed-article:9316969pubmed:meshHeadingpubmed-meshheading:9316969-...lld:pubmed
pubmed-article:9316969pubmed:meshHeadingpubmed-meshheading:9316969-...lld:pubmed
pubmed-article:9316969pubmed:meshHeadingpubmed-meshheading:9316969-...lld:pubmed
pubmed-article:9316969pubmed:meshHeadingpubmed-meshheading:9316969-...lld:pubmed
pubmed-article:9316969pubmed:meshHeadingpubmed-meshheading:9316969-...lld:pubmed
pubmed-article:9316969pubmed:meshHeadingpubmed-meshheading:9316969-...lld:pubmed
pubmed-article:9316969pubmed:meshHeadingpubmed-meshheading:9316969-...lld:pubmed
pubmed-article:9316969pubmed:meshHeadingpubmed-meshheading:9316969-...lld:pubmed
pubmed-article:9316969pubmed:meshHeadingpubmed-meshheading:9316969-...lld:pubmed
pubmed-article:9316969pubmed:meshHeadingpubmed-meshheading:9316969-...lld:pubmed
pubmed-article:9316969pubmed:meshHeadingpubmed-meshheading:9316969-...lld:pubmed
pubmed-article:9316969pubmed:meshHeadingpubmed-meshheading:9316969-...lld:pubmed
pubmed-article:9316969pubmed:meshHeadingpubmed-meshheading:9316969-...lld:pubmed
pubmed-article:9316969pubmed:meshHeadingpubmed-meshheading:9316969-...lld:pubmed
pubmed-article:9316969pubmed:year1997lld:pubmed
pubmed-article:9316969pubmed:articleTitleHalothane attenuates endothelium-dependent pulmonary vasorelaxant response to lemakalim, an adenosine triphosphate (ATP)-sensitive potassium channel agonist.lld:pubmed
pubmed-article:9316969pubmed:affiliationDivision of Anesthesiology and Critical Care Medicine, The Cleveland Clinic Foundation, Ohio 44195, USA.lld:pubmed
pubmed-article:9316969pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9316969pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:9316969pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed